Stroke Prevention in Atrial Fibrillation in Patients with Chronic Kidney Disease

Circulation

Volumn 133, Issue 15, 2016, Pages 1512-1515

  Qamar, Arman ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CREATININE; NEW DRUG; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; WARFARIN;

AGED; ATRIAL FIBRILLATION; BLOOD; CASE REPORT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS; EUROPE; FEMALE; HEART FAILURE; HEMORRHAGE; HUMAN; HYPERTENSION; METABOLISM; MYOCARDIAL INFARCTION; NORTH AMERICA; OBSERVATIONAL STUDY; REGISTER; SEVERITY OF ILLNESS INDEX; STROKE; TACHYCARDIA; THROMBOPHILIA; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; CREATININE; DIABETES COMPLICATIONS; DRUGS, INVESTIGATIONAL; EUROPE; FEMALE; HEART FAILURE; HEMORRHAGE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; NORTH AMERICA; OBSERVATIONAL STUDIES AS TOPIC; PYRAZOLES; PYRIDONES; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STROKE; TACHYCARDIA; THROMBOPHILIA; TREATMENT OUTCOME; WARFARIN;

EID: 84964515378     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018549     Document Type: Article

References (13)

1. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB, Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014 64 2471 2482. doi: 10.1016/j.jacc.2014.09.051
2. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C, Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012 367 625 635. doi: 10.1056/NEJMoa1105594
3. Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T, Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014 311 919 928. doi: 10.1001/jama.2014.1334
4. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L, Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014 129 1196 1203. doi: 10.1161/CIRCULATIONAHA.113.004777
5. Chan KE, Lazarus JM, Thadhani R, Hakim RM, Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009 20 2223 2233. doi: 10.1681/ASN.2009030319
6. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L, Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015 65 2481 2493. doi: 10.1016/j.jacc.2015.03.577
7. Eriksson BI, Quinlan DJ, Eikelboom JW, Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011 62 41 57. doi: 10.1146/annurev-med-062209-095159
8. Qamar A, Bhatt DL, Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015 11 200 202. doi: 10.1038/nrneph.2015.14
9. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012 33 2821 2830. doi: 10.1093/eurheartj/ehs274
10. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L, Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014 129 961 970. doi: 10.1161/CIRCULATIONAHA.113.003628
11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 369 2093 2104. doi: 10.1056/NEJMoa1310907
12. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM, Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011 32 2387 2394. doi: 10.1093/eurheartj/ehr342
13. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW, Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015 131 972 979. doi: 10.1161/CIRCULATIONAHA.114.014113